EQ vs KMDA

For growth investors, Kamada Ltd.

(KMDA) is the stronger pick with 12. 1% revenue growth year-over-year, versus -100. 0% for Equillium, Inc. (EQ). Kamada Ltd. (KMDA) offers the better valuation at 20. 1x trailing P/E (17. 4x forward), making it the more compelling value choice. Analysts rate Equillium, Inc. (EQ) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kamada Ltd.

(KMDA) delivered a total return of +33. 7%, compared to -54. 2% for Equillium, Inc. (EQ). Over 10 years, the gap is even starker: KMDA returned +112. 7% versus EQ's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Equillium, Inc.

(EQ) is the lower-risk stock at 0. 50β versus Kamada Ltd. 's 1. 29β — meaning KMDA is approximately 159% more volatile than EQ relative to the S&P 500. On balance sheet safety, Equillium, Inc. (EQ) carries a lower debt/equity ratio of 3% versus 4% for Kamada Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kamada Ltd.

(KMDA) is pulling ahead at 12. 1% versus -100. 0% for Equillium, Inc. (EQ). On earnings-per-share growth, the picture is similar: Kamada Ltd. grew EPS 48. 0% year-over-year, compared to -69. 6% for Equillium, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kamada Ltd.

(KMDA) is the more profitable company, earning 11. 2% net margin versus 0. 0% for Equillium, Inc. — meaning it keeps 11. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KMDA leads at 14. 5% versus 0. 0% for EQ. At the gross margin level — before operating expenses — KMDA leads at 42. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EQ: 122.

4% to $6. 25.

In this comparison, KMDA (2.

9% yield) pays a dividend. EQ does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Equillium, Inc.

(EQ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 50)). Both have compounded well over 10 years (EQ: -79. 9%, KMDA: +112. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

KMDA pays a dividend while EQ does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.